New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareAdamax vs Adipotide

Adamax vs Adipotide

Side-by-side comparison of key properties, dosing, and research.

Cognitive Enhancement
Adamax
Fat Loss & Metabolic
Adipotide
Summary
Adamax is a synthetic neuropeptide related to brain-derived neurotrophic factor (BDNF) signaling pathways. It is explored for cognitive enhancement, neuroprotection, and mood support, with proposed mechanisms involving TrkB receptor activation and enhancement of neuroplasticity similar to endogenous BDNF.
Adipotide (FTPP) is a chimeric proapoptotic peptide that selectively targets and destroys blood vessels feeding white adipose tissue. It binds prohibitin on the vasculature of fat tissue, delivering a proapoptotic sequence that induces cell death in fat-specific blood vessels, causing targeted fat tissue regression.
Half-Life
Estimated 1-3 hours (short; peptide degradation)
Estimated 2-4 hours
Admin Route
Subcutaneous, Intranasal (research)
Subcutaneous, Intravenous (research)
Research
Typical Dose
200-400 mcg per dose
Not established for humans; primate studies used 0.1-1 mg/kg
Frequency
Once daily or every other day
Daily for 4 weeks (research protocol)
Key Benefits
  • Proposed enhancement of learning and memory consolidation
  • Neuroprotective via BDNF-TrkB pathway support
  • May improve mood and resilience to stress
  • Potential support for neurogenesis
  • Cognitive clarity and focus enhancement (reported anecdotally)
  • Explored for neurodegeneration and age-related cognitive decline
  • Targeted reduction of white adipose tissue
  • Promotes fat vasculature apoptosis without systemic toxicity
  • Demonstrated significant fat loss in primate studies
  • Potential for visceral and subcutaneous fat reduction
  • Novel non-hormonal mechanism distinct from GLP-1 agonists
  • Explored for obesity and metabolic syndrome
Side Effects
  • Limited human safety data; largely anecdotal reports
  • Possible headache or mild overstimulation
  • Sleep disruption with late-day dosing
  • Unknown long-term safety profile
  • Renal toxicity observed in primate studies (transient, dose-dependent)
  • Dehydration and electrolyte imbalances in research
  • Weight regain upon cessation
  • Limited human data; side effect profile largely from animal studies
Stacks With